Artificial Intelligence is revolutionizing drug discovery and biotechnology by accelerating the identification of potential drug candidates, predicting molecular interactions, and optimizing clinical trial designs. Leveraging deep learning, generative models, and bioinformatics, AI can analyze massive datasets—from genomics to chemical libraries—at unprecedented speed. This approach reduces R&D costs, shortens development timelines, and increases the success rate of new therapies. Companies like Insilico Medicine, BenevolentAI, DeepMind, and Recursion Pharmaceuticals are at the forefront, with applications spanning oncology, rare diseases, and personalized medicine. The technology is supported by growing patent portfolios, regulatory interest, and collaborative frameworks between pharma and tech sectors.
